Skip to main content
Premium Trial:

Request an Annual Quote

Axela Biosensors, Abnova to Co-Develop Reagents for Axela's DotLab Systems

NEW YORK (GenomeWeb News) – Axela Biosensors and Abnova of Taiwan today said they plan to co-develop reagents and biomarker panels to be used on Axela's dotLab system.
 
According to the companies, the dotLab system is a real-time protein-detection technology that can accelerate the analysis, validation, and commercialization of protein biomarkers.
 
Specifically, Abnova said it will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab sensors.
 
Researchers will then be able to combine these monoclonal antibodies with their own reagents to create custom panels for multiplexed biomarker detection.
 
Financial terms of the deal were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.